All In Biotech

Drug Trial Radar · NCT07911748

A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.

A Phase Ⅰ/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS314 for Injection in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2027

Study completion Nov 2028

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MBS314, a novel asymmetric trivalent trispecific humanized antibody targeting GPRC5D, BCMA and CD3, administered by subcutaneous (SC) injection in participants with relapsed or refractory multiple myeloma. The investigational drug is MBS314 for Injection (high-concentration lyophilized formulation, 90 mg/vial, reconstituted to 90 mg/mL); this study is the first-in-human (FIH) study of this formulation. The study is divided into 2 parts: a dose escalation part (Phase I) and a dose expansion part (Phase II). In Phase I, eligible participants will be sequentially assigned to 1 of the 3 planned dose cohorts and receive MBS314 by SC injection using a step-up dosing (SUD) strategy, and dose escalation follows the Bayesian Optimal Interval (BOIN) design with a target toxicity rate of 33%. In Phase II, 1 to 3 dose groups will be selected based on Phase I results to further evaluate the efficacy of MBS314 at the recommended dose(s).

Conditions

  • Multiple Myeloma

Interventions

  • MBS314 for InjectionDrug

    Phase I: Eligible participants will be sequentially assigned to one of three dose groups under BOIN design (Dose Group 1: 3-step SUD \[0.5/3.0/15.0 mg\], target dose 90.0 mg; Dose Group 2 \[tentative\]: 3-step SUD \[1.5/9.0/45.0 mg\], target dose 135.0 mg; Dose Group 3 \[tentative\]: 3-step SUD \[2.5/15.0/90.0 mg\], target dose 180.0 mg). MBS314 is given subcutaneously (single injection volume ≤2.0 mL; injection sites ≥2 cm apart). Step-up dosing is used in Cycle 1: priming doses on C1D1, C1D4, C1D7 and target dose on C1D10. From Cycle 2 onwards, target dose is administered Q4W. Phase II: Based on Phase I findings, 1-3 dose groups will be selected for dose expansion (10-20 participants per group, total 10-60).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I :Percentage of Participants with Adverse Events (AEs)Time frame: From Baseline up to 28 (+7) days after the last dose of MBS314]
  2. Phase I:Incidence of Dose Limiting Toxicities (DLTs)Time frame: From Baseline up to 4 weeks
  3. Phase I:Maximum Tolerated Dose (MTD) (if any) or Optimal Biological Dose (OBD) of MBS314Time frame: Up to approximately 7 months
  4. Phase I:Recommended Phase Ⅱ Dose (RP2D) of MBS314Time frame: Up to approximately 7 months
  5. Phase II:Efficacy: Overall Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to approximately 15 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.